06/13/2025 | Press release | Distributed by Public on 06/13/2025 02:47
- -
FRONTEO Inc.RepresentativeBoard
of DirectorPresidentMasahiro Morimoto2-12-23
Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Growth)
Hiroyoshi Toyoshiba, Director of Director/CTO of FRONTEO, will be speaking at the NIKKEI Drug Discovery Ecosystem Summit, hosted by Keizai Shimbun.
The summit aims to identify issues Japan currently faces in terms of systems, funding, human resource development, and research and development, and to invite a wide range of stakeholders involved in drug discovery, including industry, government, academia, and the private sector, to actively discuss measures to resolve these issues in order to build a drug discovery ecosystem that will lead to stronger drug discovery capabilities. The summit aims to widely disseminate the content of these discussions and the resulting measures to society, leading to the revitalization of drug discovery innovation originating in Japan.
In the panel session "Drug discovery innovation brought about by AI and DX," Toyoshiba will speak about FRONTEO's AI drug discovery support service "FRONTEO Drug Discovery AI Factory (DDAIF)," its unique AI technology that supports the research and development of innovative new drugs, and the outlook for AI required in drug discovery.
[Event summary] Date and time: June 24th (Tue) and 25th (Wed), 2025Venue : Grand Hyatt Tokyo, online hybrid eventOfficial website: https://events.nikkei.co.jp/73199/Sponsored by: Nihon Keizai ShimbunSpecial cooperation: Japan Pharmaceutical Manufacturers Association Sponsor: Cabinet Office, Ministry of Economy, Trade and Industry, Ministry of Education, Culture, Sports, Science and Technology Support: Ministry of Health, Labor and Welfare, Astellas Pharma, Gilead Sciences, Shinsei Capital Partners, Takeda Pharmaceutical, Chugai Pharmaceutical, Novartis Pharma, Novo Nordisk Pharma, Pfizer Main speakers: Kenichiro Watanabe, Counselor, Health and Medical Strategy Promotion Secretariat, Cabinet OfficeTadayoshi Mizutani, Director , Pharmaceutical Industry Promotion and Medical Information Planning Division, Medical Affairs Bureau, Ministry of Health, Labor and WelfareHirokazu Shimoda, Director, Biochemical Industry Division, Commerce and Information Policy Bureau, Ministry of Economy, Trade and IndustryKurata, Director, Life Science Division, Research Promotion Bureau, Ministry of Education, Culture, Sports, Science and Technology Ms. Kanae Nakagama, President of the Japan Agency for Medical Research and Development (AMED) Mr. Hitoshi Nakagama, President of the Pharmaceuticals and Medical Devices Agency (PMDA) Mr. Yasuhiro Fujiwara, and others
[Toyoshiba Presentation Session]
Program: Organizer Panel Session 5 "Innovation in Drug Discovery Caused by AI and DX"
Date and time: Wednesday, February 2025, 6, 25:12-10:13
Speakers:
Kyoto University Graduate School of Medicine, Department of Human Health Sciences, Big Data Medical Sciences Professor Yasushi Okuno
Ryuwel Representative Board of Director Akira Izumi
Cancer Research Society Ariake Hospital Advanced Cancer Treatment Development Center Director Hidenobu Ishizaki Chugai
Pharmaceutical Research Division Deputy General Manager Hiroyuki Tsunoda
FRONTEO Board of Director CTO Hiroyoshi Toyoshiba
[Reference]
About FRONTEO DDAIF URL: https://lifescience.fronteo.com/products/drug-discovery-ai-factory/ "FRONTEO Drug Discovery AI Factory (DDAIF)" is an AI drug discovery support service that combines the knowledge of FRONTEO's drug discovery researchers and AI engineers with "KIBIT" (patented in Japan and the US), an AI specialized in natural language processing. It strongly supports researchers' decision-making in drug development by analyzing disease-related gene networks and building hypotheses about target candidates. This service has already been introduced at several major pharmaceutical companies and is accumulating a proven track record.
[Co-creation projects with pharmaceutical companies]
- FRONTEO and Chugai Pharmaceutical Launch Co-Creation Project for Target Discovery Using Drug Discovery AI Factory
- EA Pharma and FRONTEO launch co-creation project to explore drug discovery targets using AI
- FRONTEO and Eisai Launch Co-Creation Project for Target Discovery Using Drug Discovery AI Factory
- FRONTEO and Maruishi Pharmaceutical Launch Co-Creation Project for Biomarker Discovery Using Drug Discovery AI Factory
- FRONTEO and UBE launch co-creation project on drug repositioning using Drug Discovery AI Factory
[Joint research projects with academia]
- FRONTEO and Tokyo University of Science begin joint research to identify new drug discovery targets using the "Drug Discovery AI Factory"
- FRONTEO and Kumamoto University begin joint research to discover new cancer treatments using Drug Discovery AI Factory